Distribution, virulence attributes and antifungal susceptibility patterns of Candida parapsilosis complex strains isolated from clinical samples

Medical Mycology

Volumn 51, Issue 5, 2013, Pages 483-492

  Tosun, Ilknur ^a   Akyuz, Zeynep ^a   Guler, Nejla Cebeci ^a   Gulmez, Dolunay ^b   Bayramoglu, Gulcin ^a   Kaklikkaya, Nese ^a   Arikan Akdagli, Sevtap ^b   Aydin, Faruk ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Antifungal susceptibility; C. metapsilosis; C. orthopsilosis; Candida parapsilosis; SAPP; Virulence

Indexed keywords

ACID PROTEINASE; AMPHOTERICIN B; ANIDULAFUNGIN; ASPARTIC PROTEINASE; CASPOFUNGIN; FLUCONAZOLE; INTERNAL TRANSCRIBED SPACER; RIBOSOME RNA; TRIACYLGLYCEROL LIPASE; VIRULENCE FACTOR; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BIOFILM; CANDIDA METAPSILOSIS; CANDIDA ORTHOPSILOSIS; CANDIDA PARAPSILOSIS; CANDIDA PARAPSILOSIS SENSU STRICTO; CONTROLLED STUDY; ENZYME ACTIVITY; FUNGAL STRAIN; FUNGAL VIRULENCE; FUNGUS GROWTH; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; IN VITRO STUDY; LIPOLYSIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PROTEIN DEGRADATION; SEQUENCE ANALYSIS; SPECIES COMPARISON; SPECIES IDENTIFICATION; TOTAL PARENTERAL NUTRITION; TURKEY (REPUBLIC); YEAST;

CANDIDA; CANDIDA ALBICANS; CANDIDA METAPSILOSIS; CANDIDA ORTHOPSILOSIS; CANDIDA PARAPSILOSIS;

EID: 84879925456     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2012.745953     Document Type: Article

References (46)

1. Shin JH, Kee SJ, Shin MG, et al. Biofilm production by isolates of Candida species recovered from nonneutropenic patients: comparison of bloodstream isolates with isolates from other sources. J Clin Microbiol 2002; 40: 1244-12488.
2. Swindell K, Abdul A, Jyotsna C, Mukherjee PK, Ghannoum MA. Parenteral lipid emulsion induces germination of Candida albicans and increases biofilm formation on medical catheter surfaces. J Infect Dis 2009; 200: 473-480.
3. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133-163.
4. Tavanti A, Davidson AD, Gow NAR, Maiden MCJ, Odds FC. Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J Clin Microbiol 2005; 43: 284-292.
5. Cassone A, De BF, Pontieri E, et al. Biotype diversity of Candida parapsilosis and its relationship to the clinical source and experimental pathogenicity. J Infect Dis 1995; 171: 967-975.
6. Lockhart SR, Messer SA, Pfaller MA, et al. Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis. J Clin Microbiol 2008; 46: 2659-2664.
7. De Toro M, Torres MJ, Maite R, et al. Characterization of Candida parapsilosis complex isolates. Clin Microbiol Infect 2011; 17: 418-424.
8. Gomez-Lopez A, Alastruey-Izquierdo A, Rodriguez D, et al. Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain. Antimicrob Agents Chemother 2008; 52: 1506-1509.
9. White TJ, Bruns T, Lee S, Taylor JW. amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics. In: Innis MA, Gelfand DH, Sninsky JJ, White TJ (eds). PCR Protocols: A Guide to Methods and Applications, New York: Academic Press, 1990: 315-322.
10. Silva S, Henriques M, Oliveira R, et al. Characterization of Candida parapsilosis infection of an in vitro -reconstituted human oral epithelium. Eur J Oral Sci 2009; 117: 669-675.
11. Dostal J, Hamal P, Pavlickova L, et al. Simple method for screening Candida species isolates for the presence of secreted proteinases: a tool for the prediction of successful inhibitory treatment. J Clin Microbiol 2003; 41: 712-716.
12. Ge YP, Lu GX, Shen YN, Liu WD. I n vitro evaluation of phospholipase, proteinase, and esterase activities of Candida parapsilosis and Candida metapsilosis. Mycopathologia 2011; 172: 429-438.
13. Gacser A, Trofa D, Schafer W, Nosanchuk JD. Targeted gene deletion in Candida parapsilosis demonstrates the role of secreted lipase in virulence. J Clin Invest 2007; 117: 3049-3058.
14. Pierce CG, Uppuluri P, Tristan AR, et al. A simple and reproducible 96 well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. Nat Protoc 2008; 3: 1494-1500.
15. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, 3rd ed., approved standard M27-A3. Wayne, PA: Clinical and Laboratory Standards Institute, 2008.
16. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, 3rd suppl., M27-S3. Wayne, PA: Clinical and Laboratory Standards Institute, 2008.
17. Pfaller MA, Diekema DJ. Progress in antifungal susceptibility testing of Candida spp. using Clinical and Laboratory Standards Institute Broth Microdilution Methods, 2010-2012. J Clin Microbiol 2012; 50: 2846-2856.
18. Bernardis F, Mondello F, Millan RS, Ponton J, cassone A. Biotyping and virulence properties of skin isolates of Candida parapsilosis. J Clin Microbiol 1999; 37: 3481-3486.
19. Douglas LJ. Candida biofilms and their role in infection. Trends Microbiol 2003; 11: 30-36.
20. Gacser A, Schafer W, Nosanchuk JS, Salomon S, Nosanchuk JD. Virulence of Candida parapsilosis, Candida orthopsilosis and Candida metapsilosis in reconstituted human tissue models. Fungal Genet Biol 2007; 44: 1336-1341.
21. Orsi CF, Colombari B, Blasi E. Candida metapsilosis as the least virulent member of the " C. parapsilosis " complex. Med Mycol 2010; 48: 1024-1033.
22. Silva AP, Miranda IM, Lisboa C, Pina-Vaz C, Rodrigues AG. Prevalence, distribution and antifungal susceptibility profiles of Candida parapsilosis, C. orthopsilosis, and C. metapsilosis in a tertiary care hospital. J Clin Microbiol 2009; 47: 2392-2397.
23. Canton E, Peman J, Quindos G, et al. Prospective multicenter study of the epidemiology, molecular identification, and antifungal susceptibility of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis isolated from patients with candidemia. Antimicrob Agents Chemother 2011; 55: 5590-5596.
24. Cebeci Guler N, Tosun I, Bayramoǧlu G, Buruk K, Aydin F. Genotypic identification and distribution patterns of Candida parapsilosis complex species (C. parapsilosis sensu stricto, C. metapsilosis and C. orthopsilosis) isolated from clinical samples. Mikrobiyol Bul 2011; 45: 723-728.
25. Tavanti A, Hensgens LA, Ghelardi E, Campa M, Senesi S. Genotyping of Candida orthopsilosis clinical isolates by amplification fragment length polymorphism reveals genetic diversity among independent isolates and strain maintenance within patients. J Clin Microbiol 2007; 45: 1455-1462.
26. Ghannoum MA, Jurevic RJ, Mukherjee PK, et al. Characterization of the oral fungal microbiome (mycobiome) in healthy individuals. PloS Pathog 2010; 6: e1000713.
27. Miranda-Zapico I, Eraso E, Hern a ndez-Almaraz JL. Prevalence and antifungal susceptibility patterns of new cryptic species inside the species complexes Candida parapsilosis and Candida glabrata among blood isolates from a Spanish tertiary hospital. J Antimicrob Chemother 2011; 66: 2315-2322.
28. Kocsube S, Toth M, Vagu o lgyi C, et al. O ccurrence and genetic variability of Candida parapsilosis sensu lato in Hungary. J Med Microbiol 2007; 56: 190-195.
29. O ' Grady NP, Alexander M, Dellinger EP, et al. G uidelines for the prevention of intravascular catheter-related infections. Pediatrics 2002; 110: e51
30. Kuhn DM, Chandra J, Mukherjee PK, Ghannoum MA. Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces. Infect Immun 2002; 7: 878-888.
31. Silva S, Henriques M, Martins A, et al. Biofilms of non-Candida albicans Candida species: quantification, structure and matrix composition. Med Mycol 2009; 47: 681-689.
32. Silva S, Henriques M, Oliveira R, Williams D, Azeredo J. I n vitro biofilm activity of non- Candida albicans Candida species. Curr Microbiol 2010; 61: 534-540.
33. Lattif AA, Mukherjee PK, Chandra J, et al. Characterization of biofilms formed by C. parapsilosis, C. metapsilosis, and C. orthopsilosis. Int J Med Microbiol 2010; 300: 265-270.
34. Song JW, Shin JH, Shint DH, et al. Differences in biofilms production by three genotypes of Candida parapsilosis from clinical sources. Med Mycol 2005; 43: 657-661.
35. Neugnot V, Moulin G, Dubreucq E, Bigey F. The lipase/acyltransferase from Candida parapsilosis: molecular cloning and characterization of purified recombinant enzymes. Eur J Biochem 2002; 269: 1734- 1745.
36. Heidingsfeldova-Hruskova O, Dostal J, Majer F, et al. Two aspartic proteinases secreted by the pathogenic yeast Candida parapsilosis differ in expression pattern and catalytic properties. Biol Chem 2009; 390: 259-268.
37. Horv a th P, Nosanchuk JD, Hamari Z, V a gv o lgyi C, G a cser A. The identification of gene duplication and the role of secreted aspartyl proteinase 1 in Candida parapsilosis virulence. J Infect Dis 2012; 205: 923- 393.
38. Lin D, Wu LC, Rinaldi MG, Lehmann PF. Three distinct genotypes within Candida parapsilosis from clinical sources. J Clin Microbiol 1995, 33: 1815-1821.
39. Tavanti A, Hensgens LA, Mogavero S, et al. Genotypic and phenotypic properties of Candida parapsilosis sensu stricto strains isolated from different geographic regions and body sites. BMC Microbiol 2010; 10: 203-214.
40. Sabino R, Sampaio P, Carneiro C, Rosado L, Pais C. Isolates from hospital environments are the most virulent of the Candida parapsilosis complex. BMC Microbiol 2011; 11: 180-189.
41. Hensgens LAM, Tavanti A, Mogavero S, Ghelardi E, Senesi S. AFLP genotyping of C. metapsilosis clinical isolates: evidence for recombination. Fungal Genet Biol 2009; 46: 750-758.
42. Pfaller MA, Diekema DJ, Gibbs DL, et al. Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol 2008; 46: 842-849.
43. Pfaller MA, Chaturvedi V, Diekema DJ, et al. Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins agaist Candida spp. using new clinical breakpoints epidemiological cutoff values. Diagn Microbiol Infect Dis 2012; 73: 365-368.
44. Pfaller MA, Woosley LN, Messer SA, Jones RN, Castanheira M. Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance programme. Mycopathologia 2012; 174: 259-271.
45. Cordoba S, Vivot W, Bosco-Borgeat ME, et al. Species distribution and susceptibility profile of yeasts isolated from blood cultures: results of a multicenter active laboratory-based surveillance study in Argentina. Rev Argentina Microbiol 2011; 43: 176-185.
46. Trevi n o-Rangel RD, Garza-Gonz a lez E, Gonz a lez JG, et al. Molecular characterization and antifungal susceptibility of the Candida parapsilosis species complex of clinical isolates from Monterrey, Mexico. Med Mycol 2012; 50: 781-784.